37 results
ARS
2024 FY
CCCC
C4 Therapeutics, Inc.
30 Apr 24
Annual report to shareholders
8:52am
. Under the current PDUFA performance goals, these six- and ten-month review periods are measured from the 60-day filing date rather than the receipt date … , the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA’s review goal for a standard NDA
8-K
EX-99.1
osbj4fjg9ohwhiuqe
22 Feb 24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:15am
ARS
2ek22yma7sk gmkzagu
28 Apr 23
Annual report to shareholders
7:03am
PRE 14A
uty9mg d7rsq6zciyw
18 Apr 23
Preliminary proxy
7:59am